Stock Spotlight Archives - Page 124 of 387

FridayMar 18, 2022 12:58 pm

QualityStocksNewsBreaks – American Cannabis Partners’ Rare Approach Sets It Apart in Competitive Industry

American Cannabis Partners (“ACP”), a sustainable Jamaican experience canna-business innovator contending for first place in the U.S. cannabis industry, relies on proven strategies such as mergers and acquisitions to strengthen its position in a competitive market. For ACP, due diligence is a top priority before acquiring any assets. Its website notes that its sights are set on listings in cannabis-friendly states, cannabis population demand, agricultural zoning, available licenses, and market value. ACP purchases land and equipment in full to keep it debt-free and liquid. After completing acquisitions, the company undertakes cost-effective measures to update and appraise properties to increase market…

FridayMar 18, 2022 12:42 pm

QualityStocksNewsBreaks – StraightUp Resources Inc. (CSE: ST) (OTCQB: STUPF) Confirms Potential of Optioned Gold Properties

StraightUp Resources (CSE: ST) (OTCQB: STUPF), a precious metals explorer, has spent the past year examining the potential for gold exploration on flagship properties it has optioned in Canada’s well-known greenstone belts in Ontario, anticipating persistent demand for the metal worldwide. “Ground magnetic surveys and helicopter-borne high-resolution aerial magnetic surveys have helped confirm the potential of StraightUp’s five gold properties in the Red Lake Mining region, such as ‘multiple areas of high merit and potential mineralization’ reported in November at the Ferdinand Gold Project, which consists of 17 contiguous mining claims covering 7,143 hectares (17,651 acres),” a recent article reads.…

FridayMar 18, 2022 11:39 am

QualityStocksNewsBreaks – Nowigence Inc.’s Pluaris(TM) Enabling Users to Learn More in Less Time

Nowigence has developed an off-the-shelf, cloud-based, artificial intelligence (“AI”) platform, called Pluaris(TM), that can successfully handle more than one task at a time. While a recent Forbes article declared multitasking might not be real, Nowigence’s Pluaris is. “Relying on artificial intelligence rather than human intelligence, Pluaris can do a myriad of things simultaneously. The game-changing app automatically monitors public news sources for identified topics of interest while also gathering information together and providing summaries, extracting intelligence and creating graphical analysis. It’s the ultimate multitasking platform,” a recent article reads. “And while Pluaris automates reading and analysis of textual data, the…

FridayMar 18, 2022 11:24 am

QualityStocksNewsBreaks – Red White & Bloom Brands Inc.’s (CSE: RWB) (OTCQX: RWBYF) Acquisition Strategy Spearheading Expansion, Premium Inventory Production

Red White & Bloom Brands (CSE: RWB) (OTCQX: RWBYF), a premium cannabis brand multistate operator, has been building assets steadily in Michigan, Florida, Illinois, Massachusetts, and Arizona, while working to establish the quality and consistency that wellness consumers seek. The company announced full licensing for manufacturing both medical and adult-use cannabis products in Michigan in January, along with the closing of a lease assignment for a 15,000-square-foot manufacturing, processing and distribution facility in the city of Warren. A recent article reads: “The manufacturing facility is a key part of RWB’s acquisition strategy for 18 Michigan dispensaries, four cultivation facilities and…

ThursdayMar 17, 2022 3:05 pm

QualityStocksNewsBreaks – Mydecine Innovations Group Inc. (NEO: MYCO) (OTC: MYCOF) Playing Pivotal Role in Renaissance of Psychedelics

Mydecine Innovations (NEO: MYCO) (OTC: MYCOF), a biotechnology and digital technology company aiming to transform the treatment of mental health and addiction disorders, is among organizations, working alongside researchers at the center of the veritable renaissance of psychedelics. “Mydecine is playing a crucial role in advancing the knowledge of the benefits of psychedelics by developing innovative first- and second-generation novel compounds for the treatment of mental health and addiction and sequentially collaborating with academics to undertake vital clinical research on them. So far, Mydecine has partnered with Johns Hopkins University to launch a clinical trial utilizing psilocybin for smoking cessation. Led…

ThursdayMar 17, 2022 2:44 pm

QualityStocksNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO Discusses Significant Milestone in Advancing Berubicin

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, recently participated in the Virtual Investor 2022 Top Picks Conference. The company’s CEO John Climaco provided a corporate presentation and participated in a moderated questions and answer session during the event. Berubicin, a novel anthracycline and the first in its drug class to appear to cross the blood-brain barrier, is CNS Pharmaceuticals’ lead drug candidate. “The company is currently developing treatments using Berubicin for serious brain and central nervous system oncology indications, including glioblastoma…

WednesdayMar 16, 2022 2:25 pm

QualityStocksNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Launching Additional Rare Cannabinoids in Response to Inbound Demand

InMed Pharmaceuticals (NASDAQ: INM), a clinical-stage company developing cannabinoid-based pharmaceutical drug candidates and manufacturing technologies for pharmaceutical-grade rare cannabinoids, has dedicated itself to developing new therapeutic alternatives for the treatment of conditions with high unmet medical needs. The manufacturing process used by InMed and its recently acquired subsidiary BayMedica is unparalleled in the industry. “There is no ‘one-size-fits-all’ approach to cannabinoid manufacturing, so multiple avenues are required to realize the maximum outcome for the targeted cannabinoid. InMed and BayMedica, like a well-oiled machine, work together using biosynthesis, chemical synthesis and the proprietary IntegraSyn(TM) manufacturing models,” a recent article explains. “Together,…

WednesdayMar 16, 2022 2:04 pm

QualityStocksNewsBreaks – Laredo Oil Inc. (LRDC) Looking to Contribute to Projected Increase in US Oil Production

Laredo Oil (OTC: LRDC) is in a strong position to benefit from the forecasted growth in domestic crude oil production. The U.S. Energy Information Agency (“EIA”), in its February 2022 Short-Term Energy Outlook (“STEO”), projected that crude oil prices will remain high enough to drive U.S. crude oil production to record-high levels in 2023, reaching a forecast 12.6 million barrels per day (“b/d”), up 760,000 b/d from 2021. “Laredo is looking to contribute to increased oil production. The company’s strategy involves a focus on unlocking value when others have overlooked it, emphasizing free cash flow that allows the company to…

TuesdayMar 15, 2022 3:45 pm

QualityStocksNewsBreaks – SPYR Inc. (SPYR) Subsidiary Names New Advisory Board Member

SPYR (OTCQB: SPYR), dba SPYR Technologies, a technology company and its subsidiary, Applied Magix Inc., have appointed a new advisory board member. Fred Tio, a former senior creative director of Worldwide Marcom, Apple Inc., has accepted an invitation to serve on the Applied Magix advisory board. Applied Magix develops and resells Apple(R) ecosystem-compatible products in the growing multibillion-dollar IoT smart home and connected car markets. According to the announcement, Tio is looking forward to bringing his Apple experience and passion to the Applied Magix line of products. The company noted that Tio’s influence will be felt on the development and expansion of…

TuesdayMar 15, 2022 3:36 pm

QualityStocksNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Commencement of DehydraTECH-CBD Epilepsy Research Program

Lexaria Bioscience (NASDAQ: LEXX, LEXXW), a global innovator in drug delivery platforms, today announced that the first phase of its epilepsy research program EPIL-A21-1 is beginning this week. According to the update, the DehydraTECH(TM)-CBD test articles needed to commence dosing have already been manufactured and delivered to the third-party laboratory engaged to complete this research program. EPIL-A21-1 will assess the seizure inhibiting activity of DehydraTECH-CBD compared to the world's only FDA-approved CBD-based seizure medication, Epidiolex(R). Lexaria hopes to demonstrate superior performance based on DehydraTECH’s known advanced drug delivery capabilities. Lexaria's seizure program expects to leverage the significant gains in systemic…

Site Search

Company Search

Category: Stock Spotlight